Press Releases for NVS

Press Releases
Seasonal flu vaccine supplies spur worries
AspenBio to Present at the Lazard Capital Market 6th Annual Healthcare Conference
Bernhard Hampl, Ph.D. Elected to Serve As Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on PCP, NVS, SPR, MUR, PG and OSK
UPI NewsTrack TopNews
UPI NewsTrack TopNews
CDC: 16 million flu vaccine doses shipped
UPI NewsTrack Health and Science News
FDA approves four H1N1 vaccines
Novus Energy Inc. grants performance warrants and options
One-dose H1N1 vaccine may be on the way
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
Novus Energy Inc. announces third quarter 2009 results
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
Canada studies asthma drug Xolair risks
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Standard & Poor's annonce des modifications a l'indice compose S&P/TSX de croissance
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
RenaissanceRe Reports Net Income Available to RenaissanceRe Common Shareholders of $271.2 Million for the Second Quarter of 2009 or $4.32 Per Diluted Common Share
QLT Announces Second Quarter Results for 2009
Scientists solve a drug shelf-life problem
Feds approve U.S. sale of Ilaris
Penwest and Endo Grant Valeant Pharmaceuticals Exclusive License to Market Opana(R) ER in Canada, Australia and New Zealand; Agreement Demonstrates Value of OPANA ER in Markets Outside U.S.
Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results - Apr 29 2009 11:08AM
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results - Apr 29 2009 8:00AM
QLT Announces First Quarter Results for 2009
Beacon Equity Issues Trade Alerts on Market Movers: CBST, WDC, NVS, FDX, IBM, DNDN
QLT Names Kathryn Falberg to the Board of Directors
Zacks Sell List Highlights: Ternium, City National Corp., Novartis and IDEX Corp.
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
BenchmarkJournal.Com (Complimentary) Analyst Updates for FRE, FNM, NVS and RF
U.S. Stroke Management Products Market Will Grow From $4.8 Billion to $6.4 Billion By 2012, As Forecast By a New Medtech Insight/ Elsevier Business Intelligence Market Analysis Report
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
BridgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on NVS, JNJ, GM and DOW
New Data Show Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
Seven Summits Research Releases Comments on WMT, YHOO, X, NVS, and SWY
Novartis Pharmaceuticals Corporation's Women's Initiatives Win Healthcare Businesswomen's Association ACE Award for Corporate Programs Advancing Women's Careers
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
BeaconEquity.com Issues Technical Trade Alerts on Healthcare Stocks: ZILA, VITA, EYE, JNJ, NVS, MRK
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Zacks Analyst Blog Highlights: HCP, Inc., The Ryland Group, Inc., Alnylam Pharmaceuticals, Inc., Novartis AG and Corrections Corp. Of America
Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure - Aug 4 2008 7:59AM
Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure - Aug 4 2008 2:19AM
Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
Seven Summits Research Releases Comments on V, AMZN, NVS, EK, and TIF
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib) - May 27 2008 12:57AM
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer - May 27 2008 12:56AM
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting - May 27 2008 12:54AM
Seven Summits Research Releases Comments on RIG, HES, URBN, BCS, and NVS - May 27 2008 1:23AM
In a Phase II Study, Novartis Meningitis B Vaccine Has Potential to Produce a Protective Immune Response in Infants, the Age Group Most at Risk - Jun 2 2008 12:37AM
QLT announces first quarter results for 2008
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
Seven Summits Research Releases Comments on C, MOS, ESLR, MGM, and NVS